The Industry Standard: Intelligence for the Information Economy

  September 5, 2001
  NEWS & ANALYSIS
   Headlines
   Money & Markets
   Tech & Telecom
   Media & Marketing
   Metrics & Stats
   Policy & Politics
  SEARCH
   
  advanced search
  SERVICES
   Company Index
   Newsletters
   Wireless
  PRINT EDITION
   Read the Magazine

Home > Company Index > Drugs > Biotechnology-Medicine > AltaRex Corp.

AltaRex Corp.
 PROFILE
The disease that whispers: ovarian cancer. When diagnosed, it's often too late to treat, and standard treatments can be inadequate. AltaRex is building on research into markers associated with ovarian and other cancers to develop drugs that enhance the body's immunological response to cancer. Its treatment for ovarian cancer, OvaRex, is in late-stage clinical trials; also in trials is BrevaRex, a treatment for myeloma, lung, and prostate cancer. The drugs may have additional applicability to endometrial, breast, and non-small cell lung cancers. The company has a licensing agreement with Biomira, which spun Altarex off in 1995; it also has a deal with Dompe Farmaceutici to market OvaRex in Europe.

 COMPETITION
Centocor, Inc. (dossier)
Corixa Corporation (CRXA)
Genentech, Inc. (DNA)

 FINANCIAL OVERVIEW
Fiscal Year-End: December
2000 Sales (mil.): 0.30
1-Yr. Sales Growth: (45.3)%
Employees: 29
Revenue per employee: $10,344.83

 KEY PEOPLE
• Richard E. Bagley
    CEO
• Edward M. Fitzgerald
    CFO

 CONTACT INFO
610 Lincoln St.
Waltham, MA 02451
US
Phone: 781-672-0138
Fax: 781-672-0142
Online: Web Site

Company Data   News, quotes & more       

Hoovers Online   Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.


ADVERTISEMENT
FEATURED LINKS
Home |  Customer Service |  About Us
Australia |  Brazil |  China |  Korea |  Norway |  Poland |  Sweden |  Taiwan

Copyright ©2001 Standard Media International. Privacy Policy
Stock data provided by Stockpoint and its data suppliers. Copyright © 1995-2001